C5 and acute myocardial infarction: Pexelizumab, another monoclonal antibody targeting complement C5, initially showed promising results in early-phase II clinical trials, such as the COMMA [55] and CABG trials [56], demonstrating a 30% reduction in 30-day mortality among patients with acute myocardial infarction.